KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma

KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area

KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients

KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?Introduction

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?Q & A

KOS 2007: The Importance of New and Evolving Response Criteria

KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents